|
1.
|
Weiss RB: The anthracyclines: Will we ever
find a better doxorubicin? Semin Oncol. 19:670–686. 1992.PubMed/NCBI
|
|
2.
|
Gianni L and Valagussa P: Anthracyclines
and early breast cancer: the end of an era? J Clin Oncol.
27:1155–1157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
O’Shaughnessy J: Liposomal anthracyclines
for breast cancer: overview. Oncologist. 8(Suppl 2): 1–2. 2003.
|
|
4.
|
Liu LF: DNA topoisomerase poisons as
antitumor drugs. Annu Rev Biochem. 58:351–375. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Nitiss JL: Targeting DNA topoisomerase II
in cancer chemotherapy. Nat Rev Cancer. 9:338–350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Shan K, Lincoff AM and Young JB:
Anthracycline-induced cardiotoxicity. Ann Intern Med. 125:47–58.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Chen KM, Sun YW, Tang YW, Sun ZY and Kwon
CH: Synthesis and antitumor activity of sulfur-containing
9-anilinoacridines. Mol Pharm. 2:118–128. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Park SK, Kang H and Kwon CH:
Caspase-dependent cell death mediates potent cytotoxicity of
sulfide derivatives of 9-anilinoacridine. Anticancer Drugs.
19:381–389. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Baguley BC, Holdaway KM and Fray LM:
Design of DNA intercalators to overcome topoisomerase II-mediated
multidrug resistance. J Natl Cancer Inst. 82:398–402. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Jarvinen TA and Liu ET: Simultaneous
amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A)
genes – molecular basis for combination chemotherapy in cancer.
Curr Cancer Drug Targets. 6:579–602. 2006.
|
|
11.
|
Jorgensen JT, Nielsen KV and Ejlertsen B:
Pharmacodiagnostics and targeted therapies – a rational approach
for individualizing medical anticancer therapy in breast cancer.
Oncologist. 12:397–405. 2007.
|
|
12.
|
Smith I and Chua S: Medical treatment of
early breast cancer. IV: neoadjuvant treatment. BMJ. 332:223–224.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Nahta R and Esteva FJ: Herceptin:
mechanisms of action and resistance. Cancer Lett. 232:123–138.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Smith K, Houlbrook S, Greenall M,
Carmichael J and Harris AL: Topoisomerase II alpha co-amplification
with erbB2 in human primary breast cancer and breast cancer cell
lines: relationship to m-AMSA and mitoxantrone sensitivity.
Oncogene. 8:933–938. 1993.PubMed/NCBI
|
|
16.
|
Amaravadi RK and Thompson CB: The roles of
therapy-induced autophagy and necrosis in cancer treatment. Clin
Cancer Res. 13:7271–7279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Klionsky DJ, Abeliovich H, Agostinis P, et
al: Guidelines for the use and interpretation of assays for
monitoring autophagy in higher eukaryotes. Autophagy. 4:151–175.
2008. View Article : Google Scholar
|
|
18.
|
Baldwin EL and Osheroff N: Etoposide,
topoisomerase II and cancer. Curr Med Chem Anticancer Agents.
5:363–372. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Davis PL, Shaiu WL, Scott GL, Iglehart JD,
Hsieh TS and Marks JR: Complex response of breast epithelial cell
lines to topoisomerase inhibitors. Anticancer Res. 18:2919–2932.
1998.PubMed/NCBI
|
|
20.
|
Houlbrook S, Addison CM, Davies SL, et al:
Relationship between expression of topoisomerase II isoforms and
intrinsic sensitivity to topoisomerase II inhibitors in breast
cancer cell lines. Br J Cancer. 72:1454–1461. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Mano MS, Rosa DD, De Azambuja E, Ismael GF
and Durbecq V: The 17q12–q21 amplicon: Her2 and
topoisomerase-IIalpha and their importance to the biology of solid
tumours. Cancer Treat Rev. 33:64–77. 2007.
|
|
22.
|
Pritchard KI, Messersmith H, Elavathil L,
Trudeau M, O’Malley F and Dhesy-Thind B: HER-2 and topoisomerase II
as predictors of response to chemotherapy. J Clin Oncol.
26:736–744. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Haldane A, Holdaway KM, Finlay GJ and
Baguley BC: Cytokinetic differences in the action of
N-[2-(dimethylamino) ethyl]acridine-4-carboxamide as compared with
that of amsacrine and doxorubicin. Cancer Chemother Pharmacol.
32:463–470. 1993.
|
|
24.
|
Morse DL, Gray H, Payne CM and Gillies RJ:
Docetaxel induces cell death through mitotic catastrophe in human
breast cancer cells. Mol Cancer Ther. 4:1495–1504. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Bursch W, Ellinger A, Gerner C, Frohwein U
and Schulte-Hermann R: Programmed cell death (PCD). Apoptosis,
autophagic PCD, or others? Ann NY Acad Sci. 926:1–12. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Hoyer-Hansen M and Jaattela M: Autophagy:
an emerging target for cancer therapy. Autophagy. 4:574–580. 2008.
View Article : Google Scholar
|
|
27.
|
Yu L, Wan F, Dutta S, et al: Autophagic
programmed cell death by selective catalase degradation. Proc Natl
Acad Sci USA. 103:4952–4957. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Ma WW and Adjei AA: Novel agents on the
horizon for cancer therapy. CA Cancer J Clin. 59:111–137. 2009.
View Article : Google Scholar : PubMed/NCBI
|
